BLOCKADE OF MU-OPIOID AND KAPPA(1)-OPIOID ANALGESIC TOLERANCE BY NPC17742, A NOVEL NMDA ANTAGONIST

被引：46

作者：

KOLESNIKOV, YA

FERKANY, J

PASTERNAK, GW

机构：

[1] MEM SLOAN KETTERING CANC CTR,COTZIAS LAB NEUROONCOL,NEW YORK,NY 10021

[2] SCIOS NOVA PHARMACEUT CORP,BALTIMORE,MD

[3] CORNELL UNIV,MED CTR,COLL MED,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021

[4] CORNELL UNIV,MED CTR,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021

来源：

LIFE SCIENCES | 1993年 / 53卷 / 19期

关键词：

D O I：

10.1016/0024-3205(93)90622-A

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

NPC17742 is a potent competitive NMDA antagonist. Low doses of NPC17742 prevent the development of tolerance to repeated daily injections of the mu agonist morphine and the kappa1 agonist U50,488H. However, NPC17742 at these same doses is without effect against the kappa3 analgesic naloxone benzoylhydrazone (NalBzoH). At these doses, NPC17742 does not significantly influence morphine's ED50 value following single or repeated doses of the NMDA antagonist. The ability of NPC17742 to block tolerance to U50488H distinguishes this compound from other NMDA antagonists and raises the possibility of subclasses of NMDA antagonists. Furthermore, these results emphasize the different mechanisms involved with analgesic tolerance among mu, kappa1 and kappa3 receptors.

引用

页码：1489 / 1494

页数：6